Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments

Beyond Air announces sale of 85% of NeuroNOS to XTL Biopharmaceuticals, gaining cash, shares, and milestones, as XAIR stock jumps 165% premarket.
Nasdaq

XTL Biopharmaceuticals Expands Portfolio with Social Proxy Acquisition Amidst Regional Challenges

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...
Blockonomi

Beyond Air (XAIR) Stock Soars as Company Sells Autism Drug Platform for $32.5 Million

Beyond Air (XAIR) stock surged 150% as XTL acquired 85% of NeuroNOS for $32.5M. Trading volume jumped 363% on autism treatment platform deal.
Benzinga.com

Guide to the Top Stock-Trading Strategies

Stock traders profit from slight movements in asset prices. By entering and exiting positions with precise timing, traders can grow their portfolios over time. It may seem like luck to properly time ...
Hosted on MSN

XTL Biopharmaceuticals announces CFO transition amid strategic appointments

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...